Font Size: 

Epidemiological studies and meta-analysis have shown that several factors such as gender, age, obesity, and insulin resistance in type 2 diabetes mellitus are related to cancer incidents. Mutant p53 is scientifically proven to contribute in tumor development as gain of function while insulin that known well to play an important role in controlling body glucose levels, therefore those two biomarkers were chosen to be investigated in this study. This research aimed to study the correlation of mutant p53 and insulin in type 2 diabetes mellitus patients with cancer (n=51) and type 2 diabetes mellitus patients (n=51) in Pasar Minggu Primary Health Center and Dharmais Hospital. This research was a cross-sectional study with consecutive technique sampling and the samples were measured for its concentration of mutant p53 and insulin using ELISA Human Mutant p53 kit and ELISA Human Insulin, respectively. This study showed that there was no significant difference (p=0.774) of mutant p53 value between type 2 diabetes mellitus patients with cancer group (1.65±0.10 ng/mL) and type 2 diabetes mellitus patients group (1.62±0.09 ng/mL). However, it was significant difference (p<0.001) of insulin value in type 2 diabetes mellitus patients with cancer group (19.33±2.68 µIU/mL) and type 2 diabetes mellitus patients group (37.31±2.68 µIU/mL). There was also no significant correlation between mutan p53 and insulin value in type 2 diabetes mellitus patients with cancer group (r=0.191; p=0.179) and type 2 diabetes mellitus patients group (r=-0.081; p=0.574). Based on the results, we concluded that there was no significant difference of mutant p53 value in type 2 diabetes mellitus patients with cancer group and in type 2 diabetes mellitus patients group but there was significant difference of insulin value in both groups. There was also no significant correlation between mutan p53 and insulin value in both groups.